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Tbjectives: Lymph node status is the most important prognostic factor determining
ecurrence and survival in patients with mesothelioma and other thoracic malignan-
ies. Accurate localization of lymph node metastases is therefore necessary to
mprove selection of resectable and curable patients for surgical intervention. This
tudy investigates the potential to identify lymph node metastases intraoperatively
y using herpes-guided cancer cell–specific expression of green fluorescent protein.
ethods: After infection with NV1066, a herpes simplex virus carrying green
uorescent protein transgene, human mesothelioma cancer cell lines were assessed
or cancer cell–specific infection, green fluorescent protein expression, viral repli-
ation, and cytotoxicity. Murine models of lymphatic metastasis were established by
eans of surgical implantation of cancer cells into the preauricular (drainage to
ervical lymph nodes) and pleural (mediastinal and retroperitoneal lymph nodes)
paces of athymic mice. Fluorescent thoracoscopy, laparoscopy, and stereomicros-
opy were used to localize lymph node metastases that were confirmed by means of
mmunohistochemistry.
esults: In vitro NV1066 infected, replicated (5- to 17,000-fold), and expressed
reen fluorescent protein in all cancer cells, even when infected at a low ratio of one
iral plaque-forming unit per 100 tumor cells. In vivo NV1066 injected into primary
umors was able to locate and infect lymph node metastases producing green
uorescent protein that was visualized by means of fluorescent imaging. Histology
onfirmed lymphatic metastases, and immunohistochemistry confirmed viral pres-
nce in regions that expressed green fluorescent protein.
onclusions: Herpes virus–guided cancer cell–specific production of green fluores-
ent protein can facilitate accurate localization of lymph node metastases. Fluores-
ent filters that detect green fluorescent protein can be incorporated into operative
copes to precisely localize and biopsy lymph node metastases.
alignant pleural mesothelioma (MPM) is an aggressive cancer with a
median survival of 4 to 12 months in untreated patients.E1 In patients with
early-stage disease treated by means of surgical resection, a 5-year
urvival rate of 46% has been reported in patients who undergo extrapleural
neumonectomy and have the favorable features of epithelial histology and the
bsence of mediastinal lymph node (LN) involvement.E2 However, approximately
he Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 5 1179
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G
TS0% to 30% of patients undergo exploratory thoracotomy
ithout resection because of the unreliability of computed
omographic (CT) and magnetic resonance imaging scans in
redicting mediastinal nodal metastases and locally ad-
anced disease.E3,E4 Nodal size measured on a CT scan is
ot sensitive to determine the presence or absence of me-
astases.E3 Recent studies have shown that even positron
mission tomographic (PET) scans failed to reliably identify
he mediastinal nodal metastases.E5 Pleural tumor involving
r abutting the mediastinum might show increased fluoro-
eoxyglucose (FDG) uptake and can be misinterpreted as
odal disease.E5 Therefore any management decision based
n PET findings of N2 disease requires confirmation by
eans of surgical pathologic evaluation because of the
nown adverse effect of N2 disease on prognosis.E5 Accu-
ate localization of LN metastases is therefore necessary to
mprove selection of resectable and curable patients for
urgical intervention.E6 Cervical mediastinoscopy, thora-
oscopy, and laparoscopy have emerged as valuable diag-
ostic procedures for patients with MPM who are consid-
red candidates for surgical-based therapy.E3,E7,E8 The
evelopment of a real-time in vivo technique that might
nhance accurate detection of metastatic LNs is essential to
urther increase the sensitivity and specificity of mediasti-
oscopy and other endoscopic methods.
Herpes simplex virus (HSV) type 1–mediated oncol-
sis has emerged as a novel treatment modality against
PM.E9-E14 Studies published from our laboratory and oth-
rs have shown that these viruses are safe and effective in
educing the tumor burden both in animal modelsE9-E12 and
n human subjects.E14 Oncolysis results from the replicative
ifecycle of the virus, which lyses infected tumor cells and
eleases viral progeny for further infection and killing of
eighboring cancer cells.E15-E17 NV1066 is one such genet-
cally engineered, multimutated, replication-competent, on-
olytic HSV-1 virus.E18 We have demonstrated the efficacy
f NV1066E9,E11 and other oncolytic HSV viruses, G207
nd NV1020, in the treatment of MPM both in vitro and in
ivo. NV1066 has deletions of one copy of each of the
Abbreviations and Acronyms
CT  computed tomography
GFP  green fluorescent protein
HSV  herpes simplex virus
LN  lymph node
MOI multiplicity of infection
MPM malignant pleural mesothelioma
PBS  phosphate-buffered saline
PET  positron emission tomography
RT-PCR reverse transcriptase–polymerase chain
reactionenes ICP0, 134.5, and ICP4 to attenuate the virus from 0
180 The Journal of Thoracic and Cardiovascular Surgery ● Novatural toxicities and help ensure that it preferentially
eplicates within cancer cells.E18 Genetically engineered
erpes viruses might be useful in cancer therapy based
n their oncolytic properties aloneE9,E19 or as vectors to
arry therapeutic,E20 immunomodulatory,E21 or imaging
ransgenesE10,E22,E23 to targeted tumors. NV1066 carries
uch a marker gene, a constitutively expressed transgene for
nhanced green fluorescent protein (GFP) that is identifiable
 to 4 hours after viral entry into cells.E10,E22,E23 In the
urrent study we hypothesized that the tumor specificity of
V1066 can be exploited for detection of metastases in
Ns. In our animal models of MPM, we have demonstrated
hat the treatment of primary tumors results in the infection
nd GFP expression of metastatic tumor in LNs and aids in
heir detection.
aterials and Methods
ell Culture
he human malignant mesothelioma cell lines VAMT, H-28,
-2052, H-2373 (sarcomatoid), H-2452, H-meso (epithelioid),
-meso1A, MSTO-211H, JMN (biphasic), Meso-9, and Meso-10
ere studied. MSTO-211H cells, H28 mesothelioma cells, and
ero cells (from the African green monkey kidney) were obtained
rom the American Type Culture Collection (ATCC, Rockville,
d). H-meso and H-meso1A cell lines were obtained from the
ational Cancer Institute (NCI, Bethesda, Md). JMN, VAMT,
eso-9, and Meso-10 cell lines were a kind donation from Dr
irotnik from Memorial Sloan-Kettering Cancer Center (New
ork, NY). H-2052, H-2452, and H-2373 cell lines were a kind
onation from Dr Pass from Karmanos Cancer Institute, Wayne
tate University (Detroit, Mich). All the cell lines were grown in
ppropriate media and were incubated in a humidified incubator
upplied with 5% CO2.
irus
V1066 is a replication-competent, attenuated HSV-1 oncolytic
irus that has been described previously.E18 A single copy of the
CP4, ICP0, and 134.5 genes was deleted in NV1066 to decrease
iral virulence and increase tumor specificity. An enhanced GFP
equence under the control of a constitutive cytomegalovirus pro-
oter is inserted into the viral backbone. Because of this insertion,
V1066-infected cancer cells express green fluorescence when
bserved by means of fluorescent imaging methods.E23 All virus
reparations were formulated in D–phosphate-buffered saline
PBS) solution10% glycerin and stored at 80°C. Viral stocks
ere propagated on Vero cells, harvested by means of freeze-thaw
ysis and sonication, and titered by using a standard plaque assay.
ector Spread Assay
ector propagation, as analyzed by GFP expression, was deter-
ined by means of FACS analysis at a viral infective dose of a
ultiplicity of infection (MOI; ie, ratio of viral plaque-forming
nits to tumor cell) of 0.01, 0.1, or 1. The percentage of GFP-
ositive cells compared with control cells without viral infection
as analyzed on each day to day 7. Cells were harvested with
.25% trypsin in 0.02% ethylenediamine tetra-acetic acid, centri-
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G
TSuged, washed in PBS, and brought up in 100 L of PBS. Five
icroliters of 7-amino-actinomycin (BD Pharmingen, San Diego,
alif) was added as an exclusion dye for cell viability. Data for
FP expression was acquired on a FACS Calibur machine
quipped with Cell Quest software (Becton Dickinson, San Jose,
alif). All samples were performed in triplicate.
iral Replication Assay
he ability of the oncolytic virus to replicate within MPM cells
as evaluated by using a viral plaque assay, as described previ-
usly.E9 All samples were performed in triplicate.
ytotoxicity Assay
V1066 cytotoxicity on MPM cells was determined on each
ay for 7 days by means of a standard lactate dehydrogenase
elease bioassay. All samples were tested in 6 wells. Experi-
ents were repeated at least 3 times to ensure reproducibility.
ancer Cell–specific GFP Expression
V1066-induced GFP expression in cancer cells was assessed
y means of fluorescent microscopy. Cancer cells (5  104 in
00 L of media) were incubated in 4-well chamber slides
Lab-Tek, San Diego, Calif) and were infected with NV1066 at
OIs of 0.01, 0.1, or 1.0 in 100 L of PBS. Cells treated with
BS alone served as control cells. In additional wells, cancer
ells were coincubated with lymphocytes isolated from normal
urine LNs. Before imaging, cells were stained with 1 g/mL
f the double-stranded, DNA-specific fluorochrome Hoechst
3342 (NPE Systems, Inc, Pembroke Pines, Fla). Slides were
hen examined with a Zeiss Axiovert 200M inverted stand
icroscope (Carl Zeiss, Inc, Oberkochen, Germany) and the
etaMorph Imaging System (Universal Imaging Corp, Down-
ngtown, Pa). Identical microscopic fields were examined with
bright-field, DAPI fluorescent filter to detect Hoechst nuclear
taining and with a fluorescent filter fixed at 470  40 nm to
etect GFP expression.
nimal Experiments
nimal experiments were performed with the approval of the
emorial Sloan-Kettering Institutional Animal Care and Use
ommittee. Six- to 8-week-old male athymic mice (National
ancer Institute) were housed in temperature- and light-con-
rolled rooms. Food and water were provided ad libitum. Mice
ere anesthetized with inhalational isoflurane for all procedures
nd killed by means of CO2 inhalation at the termination of the
xperiment.
ymphatic Metastasis Animal Models
ne percent isosulfan blue dye (50 L) was injected into the
reauricular or pleural spaces of mice (n  3) to confirm the
ormal lymphatic drainage pattern in mice. Minutes after the
njection, the animals were killed, and the bilateral cervical, me-
iastinal, and retroperitoneal LN basins were surgically exposed.
raining LNs were identified by the presence of uptake of blue dye
data not shown). Lymphatic metastasis animal models were de-
eloped by means of injection of 5  106 cancer cells in 50 L of
BS into the preauricular (n  20) or intrapleural (n  20) spaces
f athymic male nude mice. Tumors were then permitted to grow S
The Journal of Thoracicor 4 to 8 weeks to allow for the development of LN metastases.
ervical, mediastinal, and retroperitoneal LN basins were exam-
ned after killing the animals.
ocalization of LN Metastases
our to 8 weeks after tumor implantation (n  20), animals
ere treated with 5  106 plaque-forming units of NV1066 in
0 L of PBS (intratumoral or intrapleural) on treatment days
and 7. Forty-eight hours after the second treatment, mice were
illed, and the LN basins were surgically exposed. These areas
ere then imaged with the Leica MZFL3 Stereomicroscope
Leica Microsystems, Wetzlar, Germany) in both bright-field
nd fluorescent modes. GFP expression is detected by using an
xcitation filter fixed at 470 nm to accommodate the excitation
eak of 475 nm and an emission filter fixed at 500 nm to
ccommodate the emission peak of 509 nm. The Retiga EX
igital CCD camera (Qimaging, Burnaby, BC, Canada) was
sed for image capture.
luorescent Thoracoscopy
e used an endoscopic system developed in collaboration with
lympus America, Inc (Scientific Equipment Division,
elville, NY), which images in both bright-field and fluores-
ent modes, permitting the detection of GFP. The mechanics of
his endoscope have been described previously.E24 A control
utton incorporated directly into the camera head enables rapid
xchange between bright-field and fluorescent modes. GFP im-
ges were taken with minimal background illumination to il-
ustrate the surrounding organs. By using this system, each
ouse (n  6) was systematically examined for the presence of
etastatic LNs, as determined by the presence of green fluo-
escence. Animals with disease treated with PBS (n  3) and
nimals without disease treated with NV1066 (n  3) were used
s negative control animals.
iral Specificity for Tumor
mmediately after tissue imaging, LNs (both green and not
reen) were harvested, embedded in Tissue-Tek O.C.T compound
Sakura Finetek, Torrance, Calif), and frozen in liquid nitrogen.
epresentative samples were also fixed in 10% buffered formalin
cetate and embedded in paraffin. The nodes (n  100) were
ectioned (8-M sections) for histologic examination. After fixa-
ion, slides were first examined under fluorescent microscopy for
FP expression and then stained with hematoxylin and eosin to
etermine whether GFP expression localized to the foci of cancer.
lternate sections that expressed GFP were stained with rabbit
olyclonal HSV-1 antibody by using a Histomouse-SP Bulk Stain-
ng Kit (Zymed Laboratories Inc, San Francisco, Calif) to confirm
hat GFP expression in LNs is indeed due to viral infection. Four
epresentative fields for each microscopic section were examined.
n institutional animal pathologist confirmed all results.
tatistical Analysis
ll data were expressed as means  standard error of the mean.
omparisons between groups were made by using the 2-tailed
tudent t test.
and Cardiovascular Surgery ● Volume 132, Number 5 1181
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G
TSesults
V1066 Infects, Expresses GFP in, Replicates in, and
yses Malignant Mesothelioma Cells
n vitro NV1066 effectively infected and expressed GFP in
PM cells (MSTO-211H) at all MOIs of 0.01, 0.1, and 1.
V1066-infected cells expressed GFP, as measured by
eans of flow cytometry (Figure 1, A) and fluorescent
icroscopy (Figure 1, B). After treatment with NV1066 at
igure 1. NV1066 infects, expresses green fluorescent protein
GFP) in, propagates in, and lyses malignant mesothelioma cells.
V1066-infected MSTO-211H mesothelioma cells express GFP, as
etermined by means of flow cytometry (A) and fluorescent mi-
roscopy (B). GFP-expressing cells increased over time, to nearly
00% at all multiplicities of infection (MOIs; A). Even when
nfected at a low MOI of 0.1 (B), over time, NV1066 replicates
ithin and propagates among mesothelioma cells, as evident by
n increasing percentage of GFP-positive cells observed under
uorescent microscopy. NV1066 effectively kills MSTO-211H cells
t all MOIs of 0.01 (circles), 0.1 (squares), or 1 (triangles), as
ssessed by means of the lactate dehydrogenase colorimetric
ytotoxicity assay. Results were expressed as percentages of
ive cells compared with control untreated cells grown under
dentical conditions.OIs of 0.01, 0.1, and 1.0 in MSTO-211H cells, 79%, 94%, 9
182 The Journal of Thoracic and Cardiovascular Surgery ● Novnd 98% of the cells, respectively, expressed GFP by day 6
Figure 1, A; P  .001 vs untreated control cells), as
easured by means of flow cytometry. NV1066 was able to
eplicate efficiently in MPM cells. After infection at MOIs
f 0.01, 0.1, and 1.0, NV1066 is able to replicate more than
7,000-fold, 1400-fold, and 64-fold compared with the ini-
ial infecting dose. After in vitro treatment with NV1066,
igher peak viral titers often occur after lower initial MOIs
ecause early cell death in the populations that are treated
ith the higher MOIs limits the cell number for productive
ellular replication of virus. With progressive viral replica-
ion and vector spread, the percentage of GFP-expressing
ells increased over time (Figure 1, B). Furthermore,
V1066 demonstrates dose- and time-dependent cytotoxic-
ty over a 100-fold range of viral doses (Figure 1, C). Three
ays after infection at an MOI of 1.0, 85%  2% of cells
ere killed. By day 7, nearly 100% of cells were killed.
even days after infection at a 10-fold lower MOI (0.1),
igure 2. NV1066 selectively infects pleural, mediastinal, and
iaphragmatic mesothelioma and spares normal tissue. After
ntrapleural administration of a single dose of NV1066, the pleural
avities of mice with macroscopic malignant mesothelioma were
xamined in bright-light (A, C, and E) and green fluorescent
rotein (GFP ; B, D, and F) modes by using fluorescent microscopic
ystems. GFP expression was localized to pleural (B), mediastinal
D), and diaphragmatic (F) mesothelioma, sparing normal tissues.6%  4% of cells were killed. Even at an MOI of 0.01,
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G
TSepresenting 1 viral particle per 100 cancer cells, 87% 4%
f cells are killed 7 days after infection. The increase in cells
illed observed at 4 to 6 days at lower MOIs of 0.01 and
.1, coinciding with increasing viral titers, indicates that
V1066 was able to successfully replicate within and prop-
gate among MPM cells. Similar results were reproduced in
ther MPM cells.
V1066 Selectively Infects and Expresses GFP
n Mesothelioma
fter intrapleural administration of NV1066, GFP expres-
ion was visualized easily by means of fluorescent micros-
opy in pleural tumor models. A single dose of virus was
ble to replicate in, spread, and infect pleural (Figure 2, A
nd B), mediastinal (Figure 2, C and D), and diaphragmatic
Figure 2, E and F) mesothelioma, sparing normal tissue.
hese representative figures demonstrate the tumor-specific
nfectious ability of NV1066 in a pleural mesothelioma
odel. Cancer cellspecific GFP expression was evident
y means of fluorescent thoracoscopy in other mice treated
ith NV1066 and is absent in mice treated with PBS.
FP Expression Can Facilitate Accurate Tumor
ocalization and Biopsy
fter the intrapleural administration of NV1066, within 48
ours fluorescent thoracoscopy (Figure 3, A) demonstrated
trong GFP expression, specifically in tumor nodules (Fig-
re 3, B). All sections that expressed GFP were found to
ave tumor cell infiltrations that correspond to the areas of
xpression. When a cross-section was taken from the frozen
issue and stained with HSV-1specific polyclonal anti-
ody, NV1066 infection (Figure 3, C) and GFP expression
Figure 3, B) were localized clearly to the cancer nodule,
nd no evidence of infection was noted in normal tissue.
ultiple sections studied from different animals confirmed
Figure 3. NV1066-induced green fluorescent protein
NV1066-induced tumor-specific GFP expression facil
thoracoscopy (A). Serial sectioning was performed and
expression to the cancer nodules (B). Corresponding c
virus (HSV-1) antibody (C). Viral infection was localized
was evident in normal tissue.imilar results. a
The Journal of ThoracicV1066 Selectively Infects Malignant Mesothelioma
ells and Spares Lymphocytes
ll MPM cells tested express GFP 2 to 12 hours after viral
nfection at all MOIs tested. The intensity of GFP expres-
ion is several logs higher than background autofluores-
) expression facilitates accurate tumor localization.
selective biopsy of pleural nodules by means of
mined with a fluorescent microscope, confirming GFP
ections were stained with polyclonal herpes simplex
e cancer nodules. No GFP expression or viral staining
igure 4. NV1066 selectively infects cancer cells and spares
ymphocytes. NV1066 selective infection of cancer cells among a
ixture of lymphocytes is confirmed by counterstaining with
mmunohistochemistry. Human mesothelioma cancer cells were
ixed with lymphocytes harvested from normal lymph nodes
LNs; A) and incubated with NV1066 for 18 hours. Live cells were
dentified by means of nuclear Hoechst staining (blue). Examina-
ion under a fluorescence microscope identified cancer cells on
he basis of expression of strong green fluorescence (B). These
esothelioma cells express integrin (CD51/61) surface antigen.
ncubation with R-phycoerythrin–conjugated mouse anti-human
D51/61 monoclonal antibody confirmed that green fluorescent
rotein (GFP ) expression is selective to only cancer cells (iden-
ified by red fluorescence; C). Overlap of fluorescent pictures with(GFP
itated
exa
ut s
to thbright field identifies cancer cells among normal cells (D).
and Cardiovascular Surgery ● Volume 132, Number 5 1183
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1
G
TSence and can be clearly delineated. We further investigated
he ability of NV1066 to induce cancer cellspecific GFP
xpression in a mixture of cells (n  6). Normal lympho-
ytes coincubated with cancer cells, and NV1066 did not
xpress GFP (control cells). Representative figures are
hown in Figure 4. Hoechst nuclear staining demonstrates
ll live cells in the incubated chamber in Figure 4, A. Cancer
ellspecific GFP expression is seen in Figure 4, B. These
esothelioma cells express integrin (CD51/61) surface an-
igen. Incubation with R-phycoerythrinconjugated mouse
nti-human CD51/61 monoclonal antibody identified me-
othelioma cells by means of red fluorescence (Figure 4, C).
verlap of fluorescent pictures confirmed that NV1066-
nduced GFP expression is isolated to cancer cells among
ormal lymphocytes (Figure 4, D). These experiments were
epeated in triplicate to ensure reproducibility.
reatment of the Primary Tumor Aids in Detection of
N Metastases
n a preauricular mouse model of MPM (Figure 5, A),
fter intratumoral injection of NV1066, the cervical area
as explored and examined under bright-field and fluo-
escent modes. Overlap of both modes demonstrates the
FP expression in NV1066-infected tumor metastases in
he LNs (Figure 5, B). The metastatic area of the LNs
xhibited intense focal expression of GFP when imaged
ith fluorescent stereomicroscopy (Figure 5, C). LNs not
arboring tumor and control LNs did not express GFP.
mmunohistochemistry confirmed viral presence (Figure
, D) in metastatic LNs. Although preauricular tumors
ere established bilaterally, tumor growth and cervical
N presence differed from animal to animal. Among the
ervical LNs, metastatic LNs were clearly identified by
Figure 5. NV1066 treatment of the primary tumor facili
(GFP) expression of the metastatic tumor in the lymph
preauricular areas of the mice (A). Four to 8 weeks afte
Mice were killed, and the cervical area was exami
GFP-expressing area of the LN is shown by an arro
expressing lymph nodes (LNs) with polyclonal HSV-1 a
LN-sparing germinal centers (D).eans of GFP expression. i
184 The Journal of Thoracic and Cardiovascular Surgery ● NovFP Expression Facilitates Minimally Invasive
etection of LN Metastases
dministration of NV1066 into the primary tumor (n  40)
ided identification of LN metastases in both the regional
tations and in distant nodes. In a model of intrapleural
PM (n  20), intrathoracic administration of NV1066 led
o selective infection and fluorescence of otherwise incon-
picuous nodal metastases in the para-aortic region (Figure 6,
 and B), as well as mediastinal (Figure 6, C and D) and
etroperitoneal (Figure 6, E and F) LN metastases. LNs that
re less than 2 mm in size, smooth in appearance, and
istologically deemed negative on a single cut section from
frozen section are considered inconspicuous for this
urpose.
V1066 Selective Infection of Tumor in LNs Is
onfirmed by Histology and Immunohistochemistry
istologic examination confirmed the presence of tumor
Figure 7, C; metastatic LN) and GFP (Figure 7, D; meta-
tatic LN) in positive LNs, as identified by means of fluo-
escent stereomicroscopy and thoracoscopy (Figure 7). Fur-
hermore, areas of GFP expression localized to tumor foci in
Ns. Absence of tumor and GFP in negative nonfluorescent
Ns (as determined by using fluorescent imaging) was
imilarly confirmed by means of microscopic analysis (Figure
, C and D; normal LN). In histologic sections expressing
FP, viral presence in metastatic LNs was confirmed by using
SV immunohistochemistry (Figure 7, E; metastatic LN).
iscussion
PM is a diffuse disease arising in the parietal and dia-
hragmatic pleura. The natural spread of mesothelioma is to
he lungs through the visceral pleura and by local extension
nto the chest wall and diaphragm. Pleural lymphatics drain
the selective infection and green fluorescent protein
es (LNs). Mesothelioma cells were injected into the
or implantation, primary tumor is treated with NV1066.
nder stereomicroscopy for GFP expression (B). The
and C). Immunohistochemical staining of the GFP-
dy identifies the viral specificity to metastatic sites intates
nod
r tum
ned u
w (B
ntibonto the internal thoracic, peridiaphragmatic, and extrapleu-
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G
TSal LNs.E25 Furthermore, diaphragmatic mesothelioma
ight also involve retroperitoneal LNs and the lymphatics
f the gastrohepatic ligament and celiac axis.E25 Extrapleu-
al nodal metastases from MPM are related to poor
urvival.E2,E5-E7,E26,E27 Patterns of tumor recurrence after
rimodality therapy for MPM reveal that 26% recur in the
eritoneum, 17% in the contralateral pleura, and 8% at
istant site.E6 Therefore it is important to accurately identify
he LN metastases in MPM to select the resectable and
urable patients for surgical intervention.E2,E3,E5,E7,E8
We introduce a novel method of real-time fluorescent
ymphatic mapping that uses cancer cell–specific viral pro-
uction of GFP to detect tumor cells in LNs. By incorpo-
ating a strain of HSV that contains the marker gene for
FP, we hope to expand the role of viral gene therapy from
ne that is purely therapeutic to one that is also diagnostic
nd can be used in surgical applications.E23,E24,E28 We have
hown that NV1066 localizes metastatic LNs after admin-
stration into the primary tumor, where it infects cancer
ells. Infection results in expression of GFP at metastatic
ites that can be visualized by using novel in vivo fluores-
Figure 6. Virally guided fluorescent detection of lymp
developed by injecting mesothelioma cells into the
implantation, mice were treated with 2 doses of NV106
and retroperitoneal and mediastinal areas were examin
F) modes. Green fluorescent protein (GFP ) expression
(LNs) that were not obvious on bright-field examination
of American Societies for Experimental Biology. Adusent imaging modalities, such as thoracoscopy and C
The Journal of Thoracicediastinoscopy.E23,E24 The real-time intraoperative detec-
ion of LN metastases distinguishes this technique from
ther LN-localizing methods. Theoretic advantages of such
technique include (1) improved accuracy and thorough
ampling of the metastatic LNs that are not obvious on
ursory examination and (2) reduced human error.
To date, we have shown that NV1066 infects and expresses
FP in more than 18 thoracic malignancy–derived cancer cell
ines.E11,E19,E24,E28,E29 GFP can be detected as early as 2 to 4
ours after viral infection. NV1066 carries “enhanced” GFP,
hich produces a stronger fluorescent signal and matures faster
han conventional GFP, reducing the lag time between syn-
hesis and detection.E23 Furthermore, amplification of the ad-
inistered viral dose enables treatment with low viral
iters.E11,E23,E24 The difference in the peaks of cellular
utofluorescence and NV1066-induced enhanced GFP reduces
he risk that autofluorescence will provide false-positive re-
ults. Detection of microscopic foci of cancer by using GFP
s quite sensitive; our in vitro data suggest that as few as 10
lustered cells might be identified, a limit of detection
ignificantly lower than that of other imaging techniques (ie,
de metastases. A pleural mesothelioma model was
ral cavities of mice. Four to 8 weeks after tumor
cted intrapleurally. After treatment, mice were killed,
nder bright-field (A, C, and E) and fluorescent (B, D and
litated easy identification of metastatic lymph nodes
d with permission: copyright © 2006 by The Federation
i et al. 2006 Fig 5, A and B ).h no
pleu
6 inje
ed u
faci
(use
umillT, magnetic resonance imaging, and PET scans cannot
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TSetect tumor foci smaller than 3-4 mm in size or approxi-
ately 1  107 cells).E24 Studies have indicated that fluo-
escent intensity ratios of 3 or greater are sufficient to
istinguish between induced fluorescence in tumors and
ackground autofluorescence in normal tissues.E24 As dem-
nstrated in this study, the fluorescent intensity ratios are
everal logs higher between infected cancer tissue and nor-
al tissue and thereby facilitate easy identification of even
icroscopic deposits by means of fluorescent thoracoscopy.
The diagnostic potential of HSV to detect microscopic
ancer is not limited by the route of administration. Biodis-
ribution studies from our laboratory using radiolabeled
irus have demonstrated that tumor-targeted delivery of
V1066 is not affected by the route of delivery (data not
ublished). Where feasible, HSV can be delivered into body
avities through a simple intrapleural or intraperitoneal in-
ection the day before. Although other LN-localizing meth-
Figure 7. Viral specificity to metastatic lymph nodes (
representative mice with pleural mesothelioma, afte
expression facilitated identification of metastatic LNs (B
and identical sections were stained with hematoxylin
and stained with herpes simplex virus (HSV-1) polyclon
was identified by an arrow (C, metastatic LN), which
specificity to the metastatic area was confirmed by
absence of GFP expression and HSV-1 antibody staini
tumor in metastatic LNs.ds are purely diagnostic, the use of oncolytic herpes vi- c
186 The Journal of Thoracic and Cardiovascular Surgery ● Novuses might confer an additional therapeutic advantage.
xtensive work in our laboratory and others has demon-
trated that oncolytic HSV strains are highly effective in the
reatment of a wide variety of experimental models of
ancer, including lung cancer,E19 esophageal cancer,E29 gas-
ric cancer,E10,E22 and MPM.E9,E11 Systemic or intrapleural
dministration of HSV resulted in reduced tumor burden
nd increased survival. Potentially, HSV used to detect
isease might also be able to reduce both primary site
ecurrence and regional nodal metastases.E18
This proof-of-concept study also demonstrates that herpes-
uided GFP detection of lymphatic metastases can be a
ighly sensitive and specific technique, comparing favor-
bly with standard methods. All sections expressing GFP
ere confirmed to be harboring tumor by means of histol-
gy and immunohistochemistry. HSV was localized to the
FP-expressing tumor, as evident by using immunohisto-
as confirmed by means of immunohistochemistry. In
1066 treatment (A), green fluorescent protein (GFP)
th normal and metastatic LNs were serially sectioned,
eosin (C), observed under fluorescent microscopy (D),
tibody (E). The presence of tumor in the metastatic LN
elated with GFP expression (D, metastatic LN). Viral
ns of immunohistochemistry (E, metastatic LN). The
normal LNs further confirmed viral specificity to theLN) w
r NV
). Bo
and
al an
corr
mea
ng inhemistry. Furthermore, GFP expression can facilitate ac-
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G
TSurate and quick identification of microscopic foci of tumor
n histologic sections without any additional need for stain-
ng, thereby enhancing the detection of tumor in frozen
ections.
One limitation of this study is the lack of data to further
efine the predicted value of this technique. Rapid and fully
utomated quantitative RT-PCR assays are being developed
o detect metastatic tumor in LNs with equal operating
haracteristics compared with conventional histology.E30
ur laboratory has demonstrated that in detecting LN me-
astases from breast cancer, HSV-guided, GFP-mediated
ymphatic mapping demonstrated favorable operating char-
cteristics (sensitivity, 80%; specificity, 96%) when com-
ared with other molecular methods (quantitative RT-PCR)
f detection.E31 Similar studies attempting to further define
he sensitivity and specificity of GFP-guided LN detection
n thoracic malignancies have been constrained by the prac-
ical limitations of quantifying pleural malignancy by means
f molecular methods and the relative inconsistency of
etastatic LN frequency.
Oncolytic herpes viruses are highly specific for infection
f cancer cells, sparing normal cells.E15,E18,E23,E24,E28,E29
he mechanisms of cancer cell–selective infection and rep-
ication of oncolytic viruses are discussed in detail else-
here.E15-E17 Investigations with NV1066 and other onco-
ytic HSV strains have shown no observable toxicity in
odent models.E18,E23,E24,E29 Furthermore, immunohisto-
hemical and PCR analyses consistently demonstrated the
bsence of viral particles in noncancerous tissues.E11,E23
he safety of HSV has been tested in preclinical toxicology
tudies in Aotus trivigatus monkeys, which are exquisitely
ensitive to wild-type herpes viral infections.E32,E33 These
onkeys demonstrated no toxicity when administered at-
enuated virus.E32,E33 Additionally, the favorable safety pro-
le of parental oncolytic HSV strains has been established
n phase I and II human clinical trials.E15,E34-E36 Preliminary
esults of a multicenter, phase I/II, open-label study of
V1020 administered by means of hepatic artery infusion
as shown an excellent safety profile in patients with colo-
ectal adenocarcinoma to the liver, and the efficacy is cur-
ently being evaluated.E37 Clinical trials with other onco-
ytic viruses pointed out hurdles, such as limitation of
ystemic distribution, intratumoral spread, and immune re-
ponses. To overcome these hurdles, we have used a mul-
imodal cancer treatment approach combining NV1066 with
tandard radiotherapy, chemotherapy, and gene therapy to
nhance antitumor efficacy without overlapping toxicities or
esistance. Diagnostic gene therapy with an oncolytic virus,
s described in this article, is an entirely new paradigm and
eeds to be assessed in future clinical trails.
This technology holds promise for improving patient
are for MPM and a number of other thoracic malignancies.
ilot studies conducted in our laboratory have shown that j
The Journal of Thoracicimilar results of fluorescent lymphatic detection are possi-
le in lung and esophageal cancer. The accurate assessment
f LN involvement in an intraoperative setting might affect
he therapeutic decision in the surgical management of
horacic malignancies.
We thank Medigene, Inc, for constructing and providing us
ith the NV1066 virus. We thank Liza Marsh of the Department
f Surgery at Memorial Sloan-Kettering Cancer Center for her
ditorial assistance. Special thanks to Kan Matsumoto from Olym-
us America, Inc, for design and construction of the fluorescent
horacoscopic system.
iscussion
r Mark J. Krasna (Baltimore, Md). I have a couple of technical
uestions, if you can answer. The article was very well written.
ne of the things that was not clear to me, though, was how large
hese animals were. It said 4 to 8 weeks. I am very impressed at
our thoracoscopic and laparoscopic skills. Can you tell us how
any kilos or grams these animals weighed?
Dr Adusumilli. These mice typically weigh 30 to 50 g. Most of
hese pictures were taken after the mice were killed. In addition,
e removed the internal organs after killing the animal, so that the
hest and abdominal cavity were well exposed. In intact animals
e injected air or carbon dioxide into the abdominal cavity to
mprove visualization.
Dr Krasna. This was still done with a 5-mm optic scope?
Dr Adusumilli. Yes.
Dr Marc Ruel (Ottawa, Canada). Can you please comment
bout the future applicability of this method to human subjects,
rst with respect to the biosafety of using such an approach and
hen with respect to the future clinical sensitivity that you expect
ith this approach, because obviously the model that you have in
he mouse has a high pretest probability for LN positivity, but what
bout in human subjects with the hardships of, for example,
uorescent thoracoscopy? Thank you.
Dr Adusumilli. I would like to first answer the question about
ensitivity. Viral infection and fluorescence are selective to cancer
ells. In this pilot study we used the immunohistochemical meth-
ds to confirm virus selectivity to cancer cells. We do know that
ight now the standard is RT-PCR, in which methods are being
eveloped to detect cancer cell tumor markers within 30 minutes.
e conducted experiments in a mouse breast cancer model and
ompared the sensitivity with that of RT-PCR. We developed
reast cancer in the mammary fat pad, treated the primary tumor
ith NV1066, and then harvested the axillary and thoracic LNs.
e tested both fluorescent and nonfluorescent LNs for tumor
arker using RT-PCR. As you can see in this slide, the initial pilot
tudies have shown a sensitivity of about 80% and a specificity of
bout 96%.
In regard to the practical limitations of fluorescent thoracos-
opy, we do know that there might be a practical problem of
etecting a micrometastasis hidden deep in an LN. Having said
hat, the GFP excitation wavelength is very specific. In the future,
uorescent endoscopy can be combined with computer detection
odels to accurately pinpoint GFP-expressing cancerous areas,ust like what is being done with FDG probes now.
and Cardiovascular Surgery ● Volume 132, Number 5 1187
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G
TSIn addition, the actual property of this virus is oncolytic. Even
f you miss the green fluorescence and micrometastases, the virus
eplicates and then kills the infected cancer cells. In vitro all 11 cell
ines were killed at a higher MOI of 1. However, as you pointed
ut, in the clinical setting we might not be able to administer an
OI of 1. Therefore we tested with an MOI of 0.01 (ie, 1 viral
laque-forming unit per 100 cancer cells). As you can see in this
epresentation, although the sensitivity differs, more than 50% of
ll the cancer cells were lysed by day 7. In regard to human
tudies, phase 1 is completed, and a multicenter phase 2 trial is in
rogress testing oncolytic HSV therapy for colorectal metastases
n the liver. We are optimistic that in addition to being a thera-
eutic tool, oncolytic HSV can be a surgeon’s tool that can be used
or diagnostic purposes.
Dr Vivek Rao (Toronto, Canada). Just to expand on the theme
f clinical applicability, correct me if I am wrong, but does this
echnique not require a direct inoculation of the primary tumor?
herefore if you take yourself to the operating room and you are
esecting, let us say, a primary lung tumor, you are not going to be
ble to identify at the time of your thoracotomy where your
etastases or potential metastases are located. Is this a technique
o come back later? And if it is a technique to come back later and
o surveillance thoracoscopy, if you remove the primary tumor,
ow do you then inoculate the patient?
Dr Adusumilli. Thank you. We intend to use the virus before
esection of the primary tumor. To ensure such applicability, we
ested 2 methods: locally by means of primary inoculation directly
nto the tumor and systemically as injections through the tail vein
f the mice and rat. Irrespective of the method, the virus is able to
nfect and fluoresce specifically in cancer cells. We also realized
he potential problem of immunity. Therefore we tested both in
mmunocompetent and immunodeficient models with systemic and
ocal injections. The local injections are much better to ensure high
nfectivity. Systemic injections were still effective, although the
nfectivity and peak of viral replication was delayed. However, the
iral specificity is still maintained. In immunocompetent animal
odels, hamster cheek pouch and SENCAR pouch, where spon-
aneous cancers arise after local application of the chemical car-
inogen, again, as you can see here, viral infection was very t
188 The Journal of Thoracic and Cardiovascular Surgery ● Novpecific to the cancer area. Therefore both in immunocompetent
nd in immunodeficient models, direct application is better than
ystemic application, and with both methods, one can still get the
esults. In the thoracic cavity, with bronchoscopic injections, CT-
uided injections, or thoracoscopic direct injections, inoculation of
he primary tumor can be achieved.
Dr Michael Chris Lekas (Toronto, Canada). I have several
uick questions. Did you look at the possibility that cells, once
hey were transfected with HSV, transformed into something even
ore aggressive and potentially malignant? I know you had im-
ressive kill ratios, but they are obviously not 100%, and in some
t was only 50%.
Dr Adusumilli. In the experimental setting, in vitro, it is
ifficult to continue the experiment beyond 7 to 9 days, and
herefore it appears that only 50% of the cells are lysed in certain
ell lines. In reality, all the infected cancer cells were lysed. The
ytotoxicity and sensitivity depend on the individual cell type,
eceptors on the cancer cell, and replicative mechanisms in the
ancer cell. At the end of the day, as long as the viral replication
s continued, the cancer cells were lysed. This is going to be the
ey in clinical applications. Initially we tested high doses, but we
anted to avoid any possible side effects. Therefore the key is
oing to be using low doses and ensuring continuation of viral
eplication localized to the tumor. This is achieved by combining
ncolytic viral therapy with radiation therapy or chemotherapy.
oth these therapies enhance stress genes in cancer cells, which
he virus uses for its advantage to enhance replication. Therefore
e believe that by using localized focused radiation or, in the case
f colorectal metastases, the phase I model, by infusing chemo-
herapy through the pump in the hepatic artery (ie, localized
hemotherapy infusions), we can keep the viral replication en-
anced in the tumor. Recently, we presented our data at the
ederation of American Societies of Experimental Biology indi-
ating that by combining with hyperthermia, oncolytic viral rep-
ication is enhanced. Therefore by combining the therapeutic mo-
alities, by localizing the virus, and by continuing the viral
eplication, even the cancer cells that are resistant to an individual
herapy can be lysed.
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